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Abstract
Obesity and metabolic syndrome (MetS) are considered chronic inflammatory states. Chemerin, a novel adipokine, may play
an important role in linking MetS and inflammation. We investigated the association of chemerin with inflammatory markers
and with characteristics of MetS in apparently healthy overweight and obese adults. We studied 92 adults; 59 men and 33
women whose average body mass index (BMI) was 28.1565.08 kg/m
2. Anthropometric parameters, insulin resistance
indices, lipid profiles, and inflammatory markers including high sensitivity C-reactive protein (hsCRP), pentraxin 3 (PTX3),
adiponectin, and chemerin were measured. Controlling for age, gender, and BMI, serum chemerin level was positively
correlated with body fat and serum triglyceride, and negatively correlated with adiponectin and high density lipoprotein
cholesterol (HDL- C), and was not correlated with altered hsCRP or PTX3 levels. Among the low, moderate and high
chemerin groups, high chemerin individuals are more likely to have lower HDL-C. Conversely, individuals in the low
adiponectin group are more likely to have lower HDL-C and show more MetS phenotypic traits than moderate and high
adiponectin subjects. To determine the relationships of chemerin and adiponectin to MetS and its components, participants
were stratified into four groups based on their chemerin and adiponectin levels (high chemerin/high adiponectin, high
chemerin/low adiponectin, low chemerin/high adiponectin, or low chemerin/low adiponectin). Participants who were in the
high chemerin/low adiponectin group more likely to have dyslipidemia and MetS (OR: 5.79, 95% CI:1.00–33.70) compared to
the other three group. Our findings suggest that chemerin and adiponectin may reciprocally participate in the development
of MetS.
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Introduction
Obesity and metabolic syndrome (MetS) are considered to be
chronic inflammatory states in which macrophages accumulate in
adipose tissue and secrete inflammatory cytokines. Several novel
inflammatory markers have been suggested to integrate metabolic
and inflammatory signals. The adipose tissue-derived proteins,
adipokines are shifted towards the proinflammatory spectrum in
obesity, and these hormonal changes may be used as early markers
of energy metabolism.
Chemerin is a recently identified adipokine [1] that is highly
expressed in liver and adipose tissue and is associated with
adiposity, insulin resistance, MetS risk factors, and degree of
nonalcoholic fatty liver [2–4]. Importantly, chemerin is thought to
regulate adipogenesis and metabolic homeostasis in murine and
human adipocytes [5]. Additionally, chemerin modulates the
innate immune system through its binding to the orphan G-
protein coupled receptor, chemokine-like receptor 1 (CMKLR1,
ChemR23) and modulates chemotaxis of immature dendritic cells
and macrophages [6–8]. Recent studies have associated chemerin
with several inflammatory markers in obesity and type-2 diabetes
[9,10] Thus, chemerin is considered a candidate in linking
inflammation to obesity-related diseases.
In recent studies, abdominal visceral fat accumulation, blood
pressure, and lipid profiles were significantly correlated with serum
chemerin levels in 173 healthy Korean individuals [11], and a
strong relationship between chemerin and key parameters of MetS
has been reported in various populations [2,4,12]. However, the
role of chemerin as a potential causative link between inflamma-
tion and MetS in overweight and obese Asian people has not been
studied.
The purpose of the current study was to: 1) investigate
associations between chemerin and MetS diagnostic parameters,
and serum levels of inflammatory and anti-inflammatory markers
including high sensitivity C- reactive protein (hsCRP), pentraxin 3
(PTX3), and adiponectin; and 2) determine whether serum
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34710chemerin is a novel predictive marker for MetS in overweight and
obese Korean adults.
Methods
This study was approved by the Institutional Ethics Review
Board at Severance Hospital and conducted according to the
principles expressed in the Declaration of Helsinki. Written
informed consent was obtained from all participants.
Subjects
We enrolled 92 healthy Korean adults whose body mass indices
(BMI) were greater than 23 kg/m
2. None of the subjects had a
previous diagnosis of diabetes, moderate to severe hypertension
(resting BP.170/100 mmHg), other cardiovascular disease,
chronic renal disease, nor acute infectious disease within the prior
6 months. All subjects were classified according to the modified
National Cholesterol Education Program (NCEP) criteria for
MetS [13], and were diagnosed as MetS patients if three or more
of the following criteria were met: 1) waist circumference (WC)
over 90 cm in men and over 80 cm in women (for Asians); 2)
systolic blood pressure $130 mmHg or diastolic pressure
$85 mmHg; 3) triglyceride $150 mg/dl; 4) high-density lipopro-
tein cholesterol (HDL-C) ,40 mg/dl for men, ,50 mg/dl for
women; or 5) fasting glucose $110 mg/dl. Subject characteristics
are summarized in Table 1.
Anthropometric measurement
BMI was calculated with dividing weight by square of height
(kg/m
2). WC was measured at the midpoint between the lower
border of the rib cage and the iliac crest. Body fat percentage was
measured by bioelectric impedance analysis equipment (Inbody
330, Biospace, Seoul, Korea). Brachial artery blood pressure was
measured with a sphygmomanometer with the subject in a sitting
position at rest for two minutes.
Blood collection and biochemical analyses
Blood samples were collected between 7:30 AM to 8:30 AM
after overnight fasting. Venous blood was collected, centrifuged,
and the separated serum was frozen immediately at 280uC.
Serum levels of fasting glucose, total cholesterol (TC), HDL-C and
triglycerides were assayed using an ADVIA 1650 Chemistry
system (Siemens, Tarrytown, NY, USA). Fasting insulin was
assayed via electrochemiluminescence immunoassay using Elecsys
2010 (Roche, Indianapolis, IN, USA). hsCRP was measured using
an ADVIA 1650 Chemistry system (Siemens, Tarrytown, NY,
USA). Insulin resistance was estimated according to the homeo-
stasis model assessment of insulin resistance (HOMA-IR), (insulin
(mIU/ml)6fasting blood glucose (mg/dl)/18)/22.5. Plasma PTX3
levels were measured using a commercially available enzyme-
linked immunosorbent assay (ELISA, R&D Systems, Minneapolis,
MN, USA), and inter- and intra-assay variability were 5.161.0%
and 4.060.4%. Serum chemerin and adiponectin levels were also
measured with an enzyme immunoassay kit (Mesdia, Seoul,
Korea), and inter- and intra-assay variability were 11.366.0% and
8.463.7% for chemerin, and the inter-assay and intra-assay
variability was 4.661.4% and 4.560.6% for adiponectin,
respectively.
Statistical analysis
SAS 9.2(SAS Institute, Cary, NC, USA) was used for statistical
analyses. The Student t test or the nonparametric Wilcoxon rank
sum test was used to compare baseline characteristics and
chemerin levels between men and women. After adjusting for
age, gender, and BMI, Pearson’s correlation coefficients and
partial correlations were calculated to evaluate the relationships
Table 1. Clinical characteristics of study subjects.
Parameter Total (n=92) Male (n=59) Female (n=33) p-value
Age 29.58(5.83) 30.0(5.61) 28.82(6.23) .354
Body mass index (kg/m
2) 28.15(5.08) 28.72(4.79) 27.14(5.49) .155
Waist circumference (cm) 94.75(12.67) 97.82(11.53) 89.26(12.93) .002
Body fat (%) 30.13(8.61) 26.78(7.29) 36.12(7.52) ,.001
SBP (mmHg) 130.7(16.6) 135.2(15.21) 122.6(16.21) ,.001
DBP (mmHg) 81.92(14.67) 86.11(13.99) 74.42(12.91) ,.001
Glucose (mg/dl) 85.09(11.54) 83.37(10.02) 88.15(13.46) .175
Insulin (mU/ml) 10.51(7.30) 10.57(7.90) 10.41(6.20) .760
HOMA-IR 2.28(1.75) 2.25(1.87) 2.34(1.54) .614
Total cholesterol (mg/dl) 193.8(36.2) 194.9(38.8) 191.9(31.68) .955
HDL-C (mg/dl) 52.73(12.36) 49.99(11.16) 57.63(13.05) .004
Triglyceride (mg/dl) 124.5(142.9) 144.8(171.3) 88.15(52.42) .002
hsCRP (mg/dL) 1.17(1.92) 0.76(1.03) 1.88(2.79) .228
PTX3 (ng/ml) 0.78(0.81) 0.81(0.82) 0.72(0.81) .478
Adiponectin (ug/ml) 4.80(2.30) 4.29(2.09) 5.73(2.40) .001
Chemerin (ng/ml) 100.3(23.5) 102.5(23.1) 96.40(24.04) .231
Data are given as mean (standard deviation). The Kolmogorov-Smirnov test was used to test the Gaussian distribution of parameters P-values were calculated by the
Student t- test (normally distributed variables; age, Body mass index, waist circumference, body fat, SBP, DBP, total cholesterol, HDL-C, and chemerin) or the
nonparametric Wilcoxon rank sum test. (non-normally distributed variables; glucose, insulin, HOMA-IR, triglyceride, hsCRP, PTX3, and adiponectin). SBP: systolic blood
pressure, DBP: diastolic blood pressure, HOMA-IR: homeostasis model assessment-insulin resistance, HDL-C: high density lipoprotein–cholesterol, hsCRP: high-sensitivity
C-reactive protein, PTX3:pentraxin 3.
doi:10.1371/journal.pone.0034710.t001
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parameters, lipid profiles, and inflammatory markers. Participants
were divided into three groups based on serum chemerin and
adiponectin level (low, moderate, high) respectively and a logistic
regression was performed to compare these three groups. To
determine the relationships of chemerin and adiponectin to MetS
and its components, we assessed the interaction analysis between
chemerin and adiponectin for MetS using likelihood-ratio tests
comparing regression models. Because the interaction terms of
chemerin with adiponectin were significant, participants were
stratified into four groups based on their chemerin and
adiponectin level (high chemerin/high adiponectin, high che-
merin/low adiponectin, low chemerin/high adiponectin, or low
chemerin/low adiponectin). ANCOVA was used to determine the
differences among the four groups based on chemerin and
adiponectin levels. Chi-squared analysis confirmed the relationship
between serum chemerin/adiponectin and the diagnosis of the
MetS. A logistic regression was used to predict the diagnosis of
MetS among four groups. The interaction between chemerin and
adiponectin was tested at a significance level of 0.10. Hypothesis
testing was two-sided at a significance level of 0.05.
Results
Table 1 shows the anthropometric and metabolic characteristics
of the participants. There was no gender difference in chemerin
levels. However, women had significantly higher serum adipo-
nectin levels and significantly lower serum triglyceride levels,
compared to men.
Significant correlations were found between chemerin and
adiposity, blood pressure, insulin resistance, lipid profiles, hsCRP,
and adiponectin; however, there were no significant correlations
between chemerin and PTX3 after adjustment for age and gender.
Serum chemerin levels were positively correlated with percentage
of body fat (r=.281, p,.05) and triglyceride levels (r=.354,
p,.05), and were negatively correlated with adiponectin
(r=2.336, p,.05) and HDL-C levels(r=2.295, p,.05), but
were not correlated with serum hsCRP nor PTX3 after additional
adjustment for BMI (Table 2).
Logistic regression analyses were performed after participants
were categorized according to their chemerin and adiponectin
levels (low, moderate, and high serum chemerin and adiponectin
levels). Unadjusted logistic regression analyses showed that the risk
of MetS increased as chemerin participants with high levels of
serum chemerin are more likely to have dyslipidemia with low
HDL-C (OR: 15.12, 95% CI: 1.58–144.5) after adjustment for
age, gender, and BMI. On the other hand, participants with low
levels of serum adiponectin are more likely to have dyslipidemia
with low HDL-C (OR: 7.11, 95% CI: 1.02–49.68) and show more
MetS phenotype (OR: 19.49, 95% CI:1.63–233.3) after adjust-
ment for age, gender, and BMI (Table 3).
These results indicate a possible reciprocal contribution of
chemerin and adiponectin to MetS. After confirming that there
was a statistically significant interaction between chemerin and
adiponectin, (data not shown) participants were stratified into four
groups based on their median levels of chemerin and adiponectin:
1) high chemerin/high adiponectin, 2) high chemerin/low
adiponectin, 3) low chemerin/high adiponectin, or 4) low
chemerin/low adiponectin, for further analyses. Based on our
initial analyses, we anticipated that participants with a high
chemerin and low adiponectin would show the worst metabolic
profiles. Indeed, this group showed the highest prevalence of MetS
compared to that of other three groups. In addition, subjects with
high chemerin/low adiponectin showed significant higher triglyc-
eride levels after controlling for age, gender, and BMI (Table 4).
To confirm the relative risk of MetS according to chemerin and
adiponectin levels, logistic regression was performed. Participants
who were in the high chemerin/low adiponectin group still
showed the highest relative risk of MetS (OR: 5.79, 95% CI:1.00–
33.70) after age, gender, and BMI adjustments (Table 5).
Discussion
Altered circulating adipokine levels can be used as early
abnormal markers, and may contribute to MetS development.
This study addressed the relationship between chemerin, a novel
adipokine, and inflammatory and anti-inflammatory markers, and
MetS criteria. We found a positive association between circulating
chemerin levels and MetS prevalence, and a consistently negative
correlation between chemerin and adiponectin levels, the latter of
which is known for its protective role in diabetes, MetS,
atherosclerosis, and various inflammatory processes [14]. When
participants were stratified into four groups based on their relative
chemerin and adiponectin levels, participants in the high
chemerin/low adiponectin group showed significantly higher
triglyceride levels and a greater incidence of MetS than other
three groups, after adjusting for age, gender, and adiposity.
Moreover, there was a statistically significant interaction between
chemerin and adiponectin and logistic regression analysis showed
that high chemerin/low adiponectin was an independent risk
factor for MetS in the current study. Based on the current
observation, we postulate a reciprocal contribution of chemerin
and adiponectin to MetS.
Table 2. Correlations between chemerin levels and other
metabolic parameters (n=92).
Parameter Model 1 Model 2
Body mass index (kg/m
2) .456* -
Waist circumference (cm) .444* .075
Body fat (%) .518* .281*
SBP (mmHg) .336* .052
DBP (mmHg) .331* .038
Glucose (mg/dl) .158 .043
Insulin (mU/ml) .424* .185
HOMA-IR .417* .179
Total cholesterol (mg/dl) .226* .174
HDL-C (mg/dl) 2.451* 2.295*
Triglyceride (mg/dl) .477* .354*
hsCRP (mg/dL) .382* .139
PTX3 (ng/ml) 2.027 .048
Adiponectin (ug/ml) 2.467* 2.336*
Coefficients are calculated using the Pearson correlation model,
*p,0.05 After glucose, insulin, HOMA-IR, triglyceride, hsCRP, PTX3, and
adiponectin were log-transformed to improve the skewness of the distribution,
Pearson’s correlation coefficients were calculated to evaluate the relationship
between chemerin levels and metabolic variables.
Model 1. Partial correlation between chemerin and other parameters after
adjustments were made for age and gender.
Model 2. Partial correlation between chemerin and other parameters after
adjustments were made for age, gender, and BMI.
SBP: systolic blood pressure, DBP: diastolic blood pressure, HOMA-IR:
homeostasis model assessment-insulin resistance, HDL-C: high density
lipoprotein –cholesterol, hsCRP: high-sensitivity C-reactive protein,
PTX3:pentraxin 3.
doi:10.1371/journal.pone.0034710.t002
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WC Low 18/30 1.00 1.00 29/31 9.67(1.94–48.28) 1.73(0.01–20.67)
Moderate 26/31 3.46(1.04–11.56) 0.62(0.10–3.77) 25/31 2.78(0.88–8.79) 2.01(0.28–14.65)
High 28/31 6.22(1.54–25.15) 1.55(0.13–18.94) 18/30 1.00 1.00
BP Low 9/30 1.00 1.00 21/31 6.90(2.22–21.42) 0.93(0.20–4.27)
Moderate 16/31 2.49(0.87–7.12) 1.09(0.30–4.04) 20/31 5.97(1.95–18.33) 2.38(0.60–9.42)
High 23/31 6.71(2.19–20.58) 1.81(0.40–8.19) 7/30 1.00 1.00
Glucose Low 2/30 1.00 1.00 3/31 1.50(0.23–9.68) 2.39(0.16–35.07)
Moderate 2/31 0.97(0.13–7.33) 0.69(0.08–6.21) 1/31 0.47(0.04–5.44) 0.60(0.04–9.35)
High 2/31 0.97(0.13–7.33) 0.70(0.06–8.47) 2/30 1.00 1.00
TG Low 1/30 1.00 1.00 14/31 9.16(1.84–45.58) 1.70(0.14–20.23)
Moderate 7/31 8.46(0.97–73.64) 4.97(0.54–46.08) 6/30 2.53(0.80–7.98) 1.98(0.27–14.41)
High 12/31 18.32(2.20–152.7) 7.30(0.75–70.34) 1/31 1.00 1.00
HDL-C Low 1/30 1.00 1.00 12/31 8.84(1.77–44.07) 7.11(1.02–49.68)
Moderate 5/31 5.58(0.61–50.91) 3.70(0.38–36.33) 6/31 3.36(0.62–18.19) 2.58(0.39–16.86)
High 14/31 23.88(2.88–198.0) 15.12(1.58–144.5) 2/30 1.00 1.00
MetS Low 2/30 1.00 1.00 15/31 27.19(3.28–225.2) 19.49(1.63–233.3)
Moderate 7/31 4.08(0.77–21.55) 1.96(0.32–11.87) 9/31 11.86(1.40–100.7) 9.90(0.91–107.3)
High 16/31 14.94(3.02–73.83) 6.03(0.97–37.72) 1/30 1.00 1.00
Logistic regression. OR: odds ratio, CI: confidence interval, PTX3:pentraxin 3, Adjusted:adjustment for age, gender, and body mass index.
WC : waist circumference .90 cm in men and .80 cm in women, BP: systolic blood pressure $130 mmHg or diastolic pressure $85 mmHg, Glucose : $110 mg/dl, TG :
triglyceride $150 mg/dl, HDL-C : high-density lipoprotein cholesterol ,40 mg/dl in men and ,50 mg/dl in women.
doi:10.1371/journal.pone.0034710.t003
Table 4. Anthropometric and metabolic parameters relative to chemerin and adiponectin levels.
Low chemerin High chemerin
High adiponectin (n=29) Low adiponectin (n=18) High adiponectin (n=17) Low adiponectin (n=28)
Waist circumference (cm) 94.84(1.00) 93.76(1.18) 95.12(1.25) 95.1(1.07)
Body fat (%) 28.76(0.80) 29.32(0.93) 31.45(0.99)* 31.27(0.85)
SBP (mmHg) 130.8(2.39) 129.5(2.79) 135.3(2.97) 128.6(2.53)
DBP (mmHg) 81.43(1.95) 82.88(2.28) 86.78(2.43) 78.85(2.07){
Glucose (mg/dl) 86.95(2.25) 85.78(2.63) 81.39(2.80) 84.96(2.39)
Insulin (mU/ml) 9.53(1.15) 10.43(1.34) 8.47(1.42) 12.82(1.21){
HOMA-IR 2.11(0.28) 2.28(0.33) 1.72(0.35) 2.80(0.30){
Total cholesterol (mg/dl) 187.2(7.21) 190.4(8.41) 184.3(8.95) 208.7(7.64){
HDL-C (mg/dl) 57.74(2.01) 51.18(2.35)* 54.78(2.50) 47.30(2.13)*{
Triglyceride (mg/dl) 83.09(27.19) 96.84(31.72) 98.00(33.76) 201.1(28.8)*{{
hsCRP (mg/dL) 0.955(0.321) 1.178(0.375) 1.033(0.399) 1.459(0.341)
PTX3 (ng/ml) 0.90(0.16) 0.51(0.19) 1.07(0.20){ 0.66(0.17)
Adiponectin (ug/ml) 6.67(0.30) 3.39(0.35)* 5.51(0.37)*{ 3.37(0.31)*{
Chemerin (ng/ml) 81.82(2.77) 85.06(3.23) 115.3(3.44)*{ 120.2(2.94)*{
Metabolic syndrome n (%) 3(10.3%) 3(16.7%) 2(11.8%) 17(60.7%)
1
Data are given as mean (standard deviation), adjusted for age, gender, and BMI. ANCOVA was used to determine the differences among four groups based on chemerin
and adiponectin levels.
1Chi-squared analysis confirmed the relationship between serum chemerin/adiponectin and MetS diagnosis.
*p,0.05 versus low chemerin/high adiponectin,
{p,0.05 versus low chemerin/low adiponectin,
{p,0.05 versus high chemerin/high adiponectin, SBP: systolic blood pressure, DBP: diastolic blood pressure, HOMA-IR: homeostasis model assessment-insulin
resistance, HDL-C: high-density lipoprotein –cholesterol, hsCRP: high-sensitivity C-reactive protein, PTX3:pentraxin 3.
doi:10.1371/journal.pone.0034710.t004
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to the development of MetS is unknown. Although it is clear that
elevated serum chemerin levels are associated with obesity or
obesity-related diseases, the regulatory mechanisms of chemerin
expression are poorly understood. Recent evidence showed that
inflammatory cytokines may play a role in chemerin release from
adipose tissue. Both IL-1b [15] and TNF-a [16] induce chemerin
mRNA expression and secretion from 3T3-L1 adipocytes in vitro,
and TNF-a increases serum total chemerin levels in wild- type
mice but not in TNF receptor superfamily 1a/1b-deficient mice in
vivo [16]. In the case of adiponectin, TNF-a decreases adiponectin
mRNA expression in adipocytes [17], and TNF-a antagonism
with etanercept in obese subjects with MetS increases both total
and high molecular weight adiponectin [18]. Together, these data
suggest that TNF-a regulates the expression of both chemerin and
adiponectin, but with opposite effects, in obesity-related inflam-
mation. These findings are supported by the fact that elevated
inflammatory cytokine levels and decreased circulating adiponec-
tin are commonly associated with obesity and MetS [14]. In
addition, our study revealed the conflicting relationship between
chemerin, adiponectin and HDL C which has anti-inflammatory
property as well as antiatherogenic functions promoting reverse
cholesterol transport [19]. Recent studies investigated the
relationship between chemerin expression and peroxisome pro-
liferator-activated receptor c (PPARc), a nuclear receptor that is a
critical regulator of adipogenesis and adipokine expression.
Rosiglitazone, a PPARc agonist, reduces expression of chemerin
selectively in mature adipocytes, both in vitro and in vivo [20].
Considering that PPARc is also a positive regulator of adiponectin
gene expression and promotes adiponectin synthesis and secretion
[21], the inverse relationship between adiponectin and chemerin
expression may represent a concomitant metabolic consequence of
PPARc activation. However, consensus has not been reached
regarding the role of PPARc activation in chemerin induction
[20,22]. Further studies are required to answer whether the
apparent reciprocal relationship between chemerin and adipo-
nectin is merely a reflection of obesity-related inflammation or is
the result of specific regulation by common mediators in
adipocytes.
As with the short pentraxin CRP, PTX3, a member of the long
pentraxin family, has been suggested to comprise a mechanistic
link between chronic low-level inflammation and obesity [23].
However, we found no association between either hsCRP or
PTX3, and chemerin levels. This may be because our study
participants were relatively healthy obese people without estab-
lished diabetes or coronary artery disease, and a chronic low-grade
inflammatory marker might not be significantly elevated. We
cannot exclude the possibility that a larger study population might
elucidate subtle relationships between CRP or PTX3 levels, and
circulating chemerin levels.
We have confirmed previous reports that increased serum
chemerin is associated with components of MetS including
elevated TG and lowered HDL-C. However, we did not find
any association between chemerin levels and insulin resistance
after controlling for age, gender and adiposity. In accordance with
our results, Bozaoglu et al. [2], reported that chemerin levels were
independently associated with MetS but not with measures of
insulin sensitivity or glucose homeostasis in people with normal
glucose tolerance. However, several studies have suggested that
chemerin represents an independent mechanism linking adipose
tissue dysfunction to impaired glucose metabolism and insulin
resistance [24,25]. Recently, Takahashi M et al. demonstrated that
insulin sensitivity was enhanced in chemerin(2/2) mice in tissue
specific manner and a pivotal transcriptional factor for b-cell
function was downregulated in chemerin-deficient islets and a
chemerin-ablated b-cell line [26]. The reason for this discrepancy
remains to be elucidated.
The cross-sectional nature of our study limits the determination
of the temporality or causality, and careful consideration of the low
statistical power with small sample sizes and case events will be
needed. In addition, we used fasting serum glucose for the
detection of diabetes instead of oral glucose tolerance test
(OGTT). Although measuring fasting serum glucose is more
convenient and reproducible than performing an OGTT, there is
a chance that overlooked impaired glucose tolerance might affect
the levels of chemerin or adiponectin. This warranted further
study. Finally, the chemerin ELISA that we used cannot
distinguish prochemerin from chemerin [27]; thus, further studies
using methods that can distinguish chemerin variants are needed
to define the exact relationship between chemerin and other
inflammatory cytokines. In lieu of these limitations, this is the first
study to provide new insights into the reciprocal contribution of
chemerin and adiponectin to MetS pathogenesis.
In summary, among apparently healthy Korean adults,
individuals with high chemerin serum levels coupled with low
circulating adiponectin are at significantly increased risk of
dyslipidemia and MetS. Further studies will clarify the efficacy
of using relative levels of adiponectin and chemerin as a novel
combination biomarker for predicting risk of MetS development.
This new approach might prove to be a valuable prognostic tool
that would complement existing strategies in evaluating a patient’s
propensity for MetS.
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Table 5. Risk of metabolic syndrome relative to chemerin and adiponectin levels.
Events/No. Unadjusted OR (95% CI) Adjusted OR (95% CI)
*
Low chemerin/High adiponectin 3/29 1.00 1.00
Low chemerin/Low adiponectin 3/18 1.73(0.31–9.69) 1.10(0.16–7.35)
High chemerin/High adiponectin 2/17 1.16(0.17–7.72) 0.46(0.05–4.16)
High chemerin/Low adiponectin 17/28 13.39(3.25–55.16) 5.79(1.00–33.70)
Logistic regression. OR: odds ratio, CI: confidence interval, PTX3:pentraxin 3,
*adjusted for age, gender, and BMI.
doi:10.1371/journal.pone.0034710.t005
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